Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure

https://doi.org/10.1016/j.amjcard.2004.07.157Get rights and content

This study sought to evaluate the utility of sildenafil in assessing pulmonary artery reactivity in left-sided cardiac failure and secondary pulmonary hypertension (PH). Fourteen consecutive patients with heart failure were studied, with oral doses of either sildenafil 25 mg (n = 8) or 50 mg (n = 6) every 8 hours for ≤3 doses, and invasive serial hemodynamic measurements were performed. Thirteen patients (93%) demonstrated >20% decreases in pulmonary artery pressures. There was also a 20% reduction of the pulmonary vascular resistance/systemic vascular resistance ratio, indicating relative pulmonary artery selectivity. Compared with sildenafil 25 mg, sildenafil 50 mg demonstrated greater reductions of pulmonary pressures. Oral sildenafil is safe and effective for the evaluation of PH reactivity in heart failure.

References (5)

There are more references available in the full text version of this article.

Cited by (90)

  • Group 2 PH: Medical Therapy

    2016, Progress in Cardiovascular Diseases
  • Treatment of pulmonary hypertension

    2016, The Lancet Respiratory Medicine
    Citation Excerpt :

    Phosphodiesterase-5 inhibitors, especially sildenafil, have also been assessed in patients with left-sided heart disease, with and without pulmonary hypertension. To many researchers, these drugs are of particular interest in these patients because the drugs not only reduce the pulmonary vascular resistance but might also improve left ventricular systolic and diastolic function.66–71 However, data from randomised controlled trials72–74 are sparse and have yielded conflicting results.

View all citing articles on Scopus
View full text